Advertisement

Advances in Therapy

, Volume 34, Issue 8, pp 1859–1875 | Cite as

Intragastric Balloon Treatment for Obesity: Review of Recent Studies

  • Chinara M. Tate
  • Allan Geliebter
Review

Abstract

Introduction

The FDA recently approved three intragastric balloon (IGB) devices, ReShape, ORBERA™, and Obalon for treatment of obesity. Given the high cost, complication risk, and invasiveness of bariatric surgery, IGB treatment may present a safer and lower cost option for weight reduction. IGBs are generally placed in the stomach endoscopically for up to 6 months to reduce gastric capacity, enhance feelings of fullness, and induce weight loss. The mechanism of action likely involves stimulation of gastric mechanoreceptors triggering short-acting vagal signals to brain regions implicated in satiety. Balloon efficacy may be influenced by balloon volume, patient gastric capacity, and treatment duration.

Methods

This review focused on eight recent (2006–present) randomized controlled trials (RCTs) comparing percentage total body weight loss (%TBWL) between IGB and control groups including three reviewed by the FDA. %TBWL based on the reviewed studies was also compared with bariatric surgery and pharmacotherapy.

Results

Of the eight IGB studies, five had balloon treatment duration of 6 months. Efficacy at 6 months, based on a pooled weighted-mean %TBWL, was 9.7%, and the control-subtracted %TBWL was 5.6%. When one study without SDs was removed, the weighted mean %TBWL was 9.3 ± 5.7% SD, and control-subtracted %TBWL was 5.5 ± 7.8%, which was statistically greater than controls. IGB showed lower efficacy than bariatric surgery (median weight loss of 27% for Rouen-Y gastric bypass (RYGB). The control-subtracted %TBWL over 6 months of 5.5–5.6% is less than the most efficacious FDA-approved weight loss drug, Qsymia. At the recommended dose, Qsymia has a placebo-subtracted %TBWL at 6 months of approximately 6.6%. The weighted mean reported incidence of serious adverse events (SAEs) in the IGB group across all eight studies was 10.5%. Only six of the eight reviewed studies reported adverse events (AEs) in the IGB group, with a pooled reported incidence of 28.2%. Recently, the FDA reported new AEs including acute pancreatitis with ReShape and ORBERA™.

Conclusion

Based on the available evidence, it is unlikely that IGB use will supplant other forms of obesity treatment. The estimated cost of endoscopic balloon implantation and retrieval is US $8,150. Collectively, a relatively small control-subtracted %TBWL and the potential for serious complications makes IGB unlikely to become widely adopted. Given the recent FDA warning, IGB longevity on the market is questionable.

Keywords

Bariatric surgery Endoscopy Gastric capacity Gastric distension Obesity Obesity treatment Qsymia Weight loss 

Notes

Acknowledgements

This review was supported in part by the National Institute of Health, Bethesda, MD, USA grants R01 DK080153 (AG). No funding or sponsorship was received for the publication of this article. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. A special thank you to Jenna Koroly, BA, for assisting with the completion of this article.

Disclosures

Chinara M. Tate has nothing to disclose. Allan Geliebter is a scientific advisor to Gelesis (Boston, MA), a company involved in developing obesity and diabetes treatments. He was a scientific advisor in 2003-5 to Fulfillium (Foster, CA), a company engaged in developing a gastric balloon, and received shares in the company, which is no longer active.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

References

  1. 1.
    Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303(3):235. doi: 10.1001/jama.2009.2014.CrossRefPubMedGoogle Scholar
  2. 2.
    American Society for Metabolic and Bariatric Surgery. Metabolic and bariatric surgery: fact sheet. 2013. https://asmbs.org/wp/uploads/2014/05/Metabolic+Bariatric-Surgery.pdf. Accessed 18 Jul 2016.
  3. 3.
    Fernandes M, Atallah AN, Soares BGO, et al. Intragastric balloon for obesity. Cochrane Database Syst Rev. 2007;(1):CD004931.Google Scholar
  4. 4.
    Benjamin SB, Boyle TM, Agus SG, et al. Small bowel obstruction and the Garren-Edwards® gastric bubble: an iatrogenic bezoar. Gastrointest Endosc. 1988;34(6):463–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Hogan RB, Johnston JH, Long BW, et al. A double-blind, randomized, sham-controlled trial of the gastric bubble for obesity. Gastrointest Endosc. 1989;35(5):381–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Schapiro M, Benjamin S, Blackburn G, et al. Obesity and the gastric balloon: a comprehensive workshop. Gastrointest Endosc. 1987;33(4):323–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Fleisher A, Conti PS, McCray RS, et al. Jejunal entrapment of a gastric balloon. JAMA. 1987;257(7):930. doi: 10.1001/jama.1987.03390070050019.CrossRefPubMedGoogle Scholar
  8. 8.
    Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis. 2015;11(4):874–81.CrossRefPubMedGoogle Scholar
  9. 9.
    Apollo Endosurgery Inc. ORBERA ™ intragastric balloon system (ORBERA ™). San Diego: Apollo Endosurgery; 2015. pp. 1–30.Google Scholar
  10. 10.
    FDA. Recently-approved devices—Obalon balloon system—P160001. Center for Devices and Radiological Health. http://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapprovalsandclearances/recently-approveddevices/ucm520741.htm. Accessed 11 Oct 2016.
  11. 11.
    Zheng Y, Wang M, He S, Ji G. Short-term effects of intragastric balloon in association with conservative therapy on weight loss: a meta-analysis. J Transl Med. 2015;13:246.Google Scholar
  12. 12.
    Moura D, Oliveira J, De Moura EGH, et al. Effectiveness of intragastric balloon for obesity: a systematic review and meta-analysis based on randomized control trials. Surg Obes Relat Dis. 2016;12(2):420–9.Google Scholar
  13. 13.
    Gaur S, Levy S, Mathus-Vliegen L, Chuttani R. Balancing risk and reward: a critical review of the intragastric balloon for weight loss. Gastrointest Endosc. 2015;81(6):1330–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. Mass Med Soc. 2009. doi: 10.1056/NEJMoa0804748.Google Scholar
  15. 15.
    Genco A, Maselli R, Casella G, Cipriano M, Redler A. Intragastric balloon treatment for obesity. In: Obesity, bariatric and metabolic surgery. Cham: Springer International Publishing; 2016. pp. 485–92. doi: 10.1007/978-3-319-04343-2_50.
  16. 16.
    Karmali S, Birch DW, Sharma AM. Is it time to abandon excess weight loss in reporting surgical weight loss? Surg Obes Relat Dis. 2009;5(4):503–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Mohammed M. Effects of intragastric balloon versus conservative therapy on appetite regulatory hormones in obese subjects. Trends Med Res. 2014;1:1–5.Google Scholar
  18. 18.
    Farina MG, Baratta R, Nigro A, et al. Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obes Surg. 2012;22(4):565–71. doi: 10.1007/s11695-011-0514-y.CrossRefPubMedGoogle Scholar
  19. 19.
    Abu Dayyeh BK, Eaton LL, Woodman G, et al. 144 A randomized, multi-center study to evaluate the safety and effectiveness of an intragastric balloon as an adjunct to a behavioral modification program, in comparison with a behavioral modification program alone in the weight management of obese subject. Gastrointest Endosc. 2015;81(5):AB147.CrossRefGoogle Scholar
  20. 20.
    Mathus-Vliegen EMH, Eichenberger RI. Fasting and meal-suppressed ghrelin levels before and after intragastric balloons and balloon-induced weight loss. Obes Surg. 2014;24(1):85–94. doi: 10.1007/s11695-013-1053-5.CrossRefPubMedGoogle Scholar
  21. 21.
    Fuller NR, Pearson S, Lau NS, et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. Obesity. 2013;21(8):1561–70. doi: 10.1002/oby.20414.CrossRefPubMedGoogle Scholar
  22. 22.
    Higgins JPT, Green SE, Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley-Blackwell; 2011.Google Scholar
  23. 23.
    Genco A, Cipriano M, Bacci V, et al. BioEnterics® Intragastric Balloon (BIB®): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes. 2006;30(1):129–33. doi: 10.1038/sj.ijo.0803094.CrossRefGoogle Scholar
  24. 24.
    Martinez-Brocca MA, Belda O, Parejo J, et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obes Surg. 2007;17(5):649–57.Google Scholar
  25. 25.
    Courcoulas A, Dayyeh BA, Eaton L, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes (Lond). 2017;41(3):427–33.Google Scholar
  26. 26.
    NHLBI. The practical guide identification, evaluation, and treatment of overweight and obesity in adults. https://www.nhlbi.nih.gov/files/docs/guidelines/prctgd_c.pdf. Accessed 2 May 2017.
  27. 27.
    Shoar S, Saber AA. Long-term and midterm outcomes of laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass: a systematic review and meta-analysis of comparative studies. Surg Obes Relat Dis. 2017;13(2):170–80.CrossRefPubMedGoogle Scholar
  28. 28.
    Chang S-H, Stoll CRT, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg. 2014;149(3):275–87.Google Scholar
  29. 29.
    CONQUER Clinical Study | Qsymia® (Phentermine and Topiramate extended-release) Capsules CIV. https://qsymia.com/hcp/efficacy/study-2-conquer/. Accessed 8 May 2017.
  30. 30.
    Laursen SB, Leontiadis GI, Stanley AJ, Møller MH, Hansen JM, Schaffalitzky de Muckadell OB. Relationship between timing of endoscopy and mortality in patients with peptic ulcer bleeding: a nationwide cohort study. Gastrointest Endosc. 2017;85(5):936.e3–44.e3.CrossRefGoogle Scholar
  31. 31.
    Abu Dayyeh BK, Kumar N, Edmundowicz SA, et al. ASGE bariatric endoscopy task force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425.e5–38.e5.CrossRefGoogle Scholar
  32. 32.
    Robinson OG, Benos DJ, Mazzochi C. Spontaneous autoinflation of saline mammary implants: further studies. Aesthetic Surg J. 2005;25(6):582–6.CrossRefGoogle Scholar
  33. 33.
    Seng P, Bayle S, Alliez A, Romain F, Casanova D, Stein A. The microbial epidemiology of breast implant infections in a regional referral centre for plastic and reconstructive surgery in the south of France. Int J Infect Dis. 2015;35:62–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Misiakos EP, Bagias G, Patapis P, Sotiropoulos D, Kanavidis P, Machairas A. Current concepts in the management of necrotizing fasciitis. Front Surg. 2014;1:36.Google Scholar
  35. 35.
    Haberman Associates. Vivus’ Qsymia (formerly Qnexa) approved by the FDA—the most efficacious weight-loss drug ever approved in the USA. Biopharmconsortium Blog. http://biopharmconsortium.com/2012/07/26/vivus-qsymia-formerly-qnexa-approved-by-the-fda-the-most-efficacious-weight-loss-drug-ever-approved-in-the-u-s/. Accessed 2 May 2017.
  36. 36.
    Shayani V, editor. Gastric balloon: insurance & costs. Bariatric Surgery Source. 2017. http://www.bariatric-surgery-source.com/gastric-balloon.html. Accessed 8 May 2017.
  37. 37.
    Cho Y-S, Kim H-K, Jang E-C, et al. Usefulness of the bedside index for severity in acute pancreatitis in the early prediction of severity and mortality in acute pancreatitis. Pancreas. 2013;42(3):483–7.Google Scholar
  38. 38.
    Ozaki N, Sengupta JN, Gebhart GF, et al. Mechanosensitive properties of gastric vagal afferent fibers in the rat. J Neurophysiol. 1999;82(5):2210–20.Google Scholar
  39. 39.
    Cubattoli L, Barneschi C, Mastrocinque E, Bonucci P, Giomarelli PP. Cardiac arrest after intragastric balloon insertion in a super-obese patient. Obes Surg. 2009;19(2):253–6. doi: 10.1007/s11695-008-9606-8.CrossRefPubMedGoogle Scholar
  40. 40.
    Mussa BM, Verberne AJM. The dorsal motor nucleus of the vagus and regulation of pancreatic secretory function. Exp Physiol. 2013;98(1):25–37. doi: 10.1113/expphysiol.2012.066472.CrossRefPubMedGoogle Scholar
  41. 41.
    Wang G-J, Tomasi D, Backus W, et al. Gastric distention activates satiety circuitry in the human brain. Neuroimage. 2008;39(4):1824–31.CrossRefPubMedGoogle Scholar
  42. 42.
    Geliebter A, Westreich S, Gage D. Gastric distension by balloon and test-meal intake in obese and lean subjects. Am J Clin Nutr. 1988;48(3):592–4.PubMedGoogle Scholar
  43. 43.
    Geliebter A, Melton PM, Gage D, McCray RS, Hashim SA. Gastric balloon to treat obesity: a double-blind study in nondieting subjects. Am J Clin Nutr. 1990;51(4):584–8.Google Scholar
  44. 44.
    Granström L, Backman L. Stomach distension in extremely obese and in normal subjects. Acta Chir Scand. 1985;151(4):367–70.Google Scholar
  45. 45.
    Geliebter A, Westreich S, Gage D, Hashim SA. Intragastric balloon reduces food intake and body weight in rats. Am J Physiol. 1986;251(2):R794–7.PubMedGoogle Scholar
  46. 46.
    Geliebter A, Melton PM, McCray RS, et al. Clinical trial of silicone-rubber gastric balloon to treat obesity. Int J Obes. 1991;15(4):259–66.PubMedGoogle Scholar
  47. 47.
    Lopez-Nava G, Rubio MA, Prados S, et al. BioEnterics intragastric balloon (BIB). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg. 2011;21(1):5–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Shelby VS, James MS, George W, Steven E, Tarek I, Shayani H. The Obalon swallowable 6-month balloon system is more effective than moderate intensity lifestyle therapy alone: results from a 6-month randomized sham controlled trial. In: Digestive disease week. San Diego; 2016. http://www.ddw.org/program/online-planner.
  49. 49.
    Mion F, Ibrahim M, Marjoux S, et al. Swallowable Obalon® gastric balloons as an aid for weight loss: a pilot feasibility study. Obes Surg. 2013;23(5):730–3.Google Scholar
  50. 50.
    Nobili V, Corte CD, Liccardo D, et al. Obalon intragastric balloon in the treatment of paediatric obesity: a pilot study. Pediatr Obes. 2015;10(5):e1–4.CrossRefPubMedGoogle Scholar
  51. 51.
    Machytka E, Chuttani R, Bojkova M, et al. Elipse™, a procedureless gastric balloon for weight loss: a proof-of-concept pilot study. Obes Surg. 2016;26:512–6.CrossRefPubMedGoogle Scholar
  52. 52.
    Gaur S. Elipse system receives European marketing approval—Allurion Technologies. 2015. https://allurion.com/2015/12/08/elipse-receives-europe-marketing-approval/. Accessed 10 May 2017.
  53. 53.
    Galanti K, Gluck ME, Geliebter A. Test meal intake in obese binge eaters in relation to impulsivity and compulsivity. Int J Eat Disord. 2007;40(8):727–32.CrossRefPubMedGoogle Scholar
  54. 54.
    Geliebter A, Yahav E, Gluck M, Hashim S. Gastric capacity, test meal intake, and appetitive hormones in binge eating disorder. Physiol Behav. 2004;81(5):735–40.Google Scholar

Copyright information

© Springer Healthcare 2017

Authors and Affiliations

  1. 1.Department of Psychiatry, Mt. Sinai St. Luke’sIcahn School of Medicine at Mt. SinaiNew YorkUSA
  2. 2.Department of PsychologyTouro College and University SystemNew YorkUSA

Personalised recommendations